News - Xenon Pharmaceuticals, Pharmaceutical


Popular Filters

Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon


US pharma giant Merck & Co (NYSE: MRK) has entered into a non-exclusive agreement with drug major Bristol-Myers…

Anti-viralsBristol-Myers SquibbCardio-vasculardaclatasvirLicensingMerck & CoMK-5172PharmaceuticalResearchXenon Pharmaceuticals

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million


Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's…

CopaxoneFinancialGenericsLicensingPatentsPharmaceuticalResearchTeva Pharmaceutical IndustriesXenon Pharmaceuticals

Xenon in $646 million deal with Roche unit


Canada based Xenon Pharmaceuticals, a privately-owned, clinical genetics-based drug discovery and development…

BiotechnologyGenentechLicensingNeurologicalPharmaceuticalResearchRocheXenon Pharmaceuticals

Back to top